HR Execs on the Move

Sagimet

www.sagimet.com

 
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sagimet.com
  • 155 Bovet Road, Suite 303
    San Mateo, CA USA 94402
  • Phone: 650.561.8600

Executives

Name Title Contact Details
Dennis Hom
Chief Financial Officer and Head Corporate Development Profile
Anthony Rimac
Chief Financial Officer Profile
George Kemble
Chief Executive Officer Profile

Similar Companies

Helix Medical Communication

Helix Medical Communication is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hillsides

Hillsides is a premier provider dedicated to improving the overall well-being and functioning of vulnerable children, youth, and their families.

Gorbec Pharmaceuticals Services

Gorbec Pharmaceuticals Services is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Kalypsys

Kalypsys is a clinical stage pharmaceutical company that is advancing the way drugs are discovered and developed. We seamlessly integrate our capabilities in drug discovery, medicinal chemistry and translational medicine with proprietary automated